Doctor of Philosophy, The Ohio State University, 2024, Biomedical Sciences
Cancer is a complex disease that arises from acquired mutations in normal cells, resulting in uncontrolled cell growth. The body harbors defensive mechanisms to prevent cancer cells from proliferating by repairing mistakes in DNA replication and eradicating abnormal pre-cancerous cells. However, cancer cells can acquire mutations that allow them to surpass this defensive barrier and continue to develop into a malignant disease. Since cancer develops from diverse alterations, the tumor biology of each patient is unique, facilitating a need for customizable treatments. Fortunately, genomic sequencing has enabled researchers and clinicians to identify and target the genomic alterations driving individual patients' cancers. Targeted therapy, including immunotherapy and tyrosine kinase inhibitors, have significantly improved the overall survival and quality of life of cancer patients. Established biomarkers associated with good response to a specific treatment help guide treatment. For example, established biomarkers for immune checkpoint inhibitor therapy, a type of immunotherapy, includes tumor mutational burden, microsatellite instability, and immunohistochemistry of programmed cell death ligand 1 (PD-L1). Many gene fusions and short variants involving kinase genes, including ALK, ROS1, FGFR1, FGFR2, FGFR3, RET, NTRK1, NTRK2, and NTRK3, can be targeted with clinically-approved tyrosine kinase inhibitors (TKIs). However, not all patients are eligible for targeted therapy. In this work, we strive to expand this eligibility by identifying and describing oncogenic alterations that may be clinically targetable, with a focus on specific type of genomic alteration. Structural variations, which are rare chromosomal rearrangements that can lead to carcinogenesis, include copy number variations, large deletions, tandem duplications, large insertions, and translocations, otherwise known as gene fusions. Here, leveraging large data sources, we identify and describe rare oncogeni (open full item for complete abstract)
Committee: Sameek Roychowdhury (Advisor); Daniel Stover (Committee Member); Lianbo Yu (Committee Member); Robert Baiocchi (Committee Member); Amanda Toland (Committee Member)
Subjects: Bioinformatics; Biology; Genetics; Medicine